Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385050 | 0.96 | LMNA (0.48) | L3MBTL1MCL1LMNAKMT2AUSP2 | |
| Oxalic Acid SCHEMBL7990786 | 0.93 | KDM4E (0.52) | L3MBTL1MCL1LMNAKMT2AUSP2 | |
| SCHEMBL7989019 | 0.87 | LMNA (0.54) | L3MBTL1LMNAUSP2HTTHSD17B10 | |
| SCHEMBL224970 | 0.85 | LMNA (0.50) | L3MBTL1LMNAKMT2AUSP2HTT | |
| SCHEMBL8795871 | 0.85 | GGPS1 (0.37) | — | |
| SCHEMBL4387266 | 0.84 | CHRM5 (0.37) | HSD17B10 | |
| SCHEMBL7974390 | 0.84 | TAAR1 (0.43) | GAA | |
| SCHEMBL7977252 | 0.83 | NOS1 (0.47) | MCL1LTA4H | |
| SCHEMBL7994413 | 0.82 | HCAR2 (0.41) | HSD17B10 | |
| SCHEMBL4379848 | 0.82 | KMT2A (0.38) | L3MBTL1LMNAKMT2AKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | claimed |
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | claimed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | claimed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-0760811-B1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 MODULATORS | INST NAT SANTE RECH MED (FR) | 2009-11-18 | — | — | EP | disclosed |
| EP-0760811-B1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 MODULATORS | INST NAT SANTE RECH MED (FR) | 2009-11-18 | — | — | EP | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0485636-B1 | INDOLE DERIVATIVE | TORAY INDUSTRIES (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0735026-A1 | Method for the production of isoquinoline derivatives and their use as intermediates in the preparation of indole derivatives | TORAY INDUSTRIES, INC. (JP) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | disclosed |
| US-5539119-A | MULTISTAGE FORMATION BY OXIDATION, REDUCING A CARBAMATE TO FORM AN ENAMINE, FORMING AN OXIDE | TORAY INDUSTRIES, INC. (JP) | 1996-07-23 | — | — | US | disclosed |
| US-5244904-A | Immunorepressant, analgesic | TORAY INDUSTRIES, INC. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0485636-A1 | INDOLE DERIVATIVE | TORAY INDUSTRIES, INC. (JP) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | L3MBTL1 1288/4885MCL1 4522/4885LMNA 1714/4885 |
| US-20100234397-A1 | ENZYME INHIBITORS | ACHE, MAOA, BACE1 | L3MBTL1 2212/4885MCL1 4737/4885LMNA 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.